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ABSTRACT 
The objective of the current work is to develop and evaluate the effect of cross linking on drug release of chitosan pellets of Glipizide. Hence the 
present work was aimed to formulate glipizide pellets with a view to achieve and to maintain the plasma concentration for considerable period 
by controlling the release so to decrease the occurrence of doses and also to recover the patient fulfillment. Here the pellets of glipizide are 
designed by Pan Coating technique with solution layering with and without cross linking by Gluteraldehyde effectively. Then the optimized 
formulations are aimed to study the effects of polymer and cross linking on different evaluation parameters including the dru g release study. 
Finally the conclusion was to arrive at better formulation based on comparison amongst the studied ones. 
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INTRODUCTION  
Pellets are used in decrease of dosage course of therapy and 
gastrointestinal annoyance, in addition controlling the drug 
discharge and escalating the absorption of the active 
component, moreover some of the useful properties of the 
pellet formulations are being excellent candidates for the 
release of the drug substances due to minimizing the dose 
clearance effect. The reproducibility of the discharge 
distinctiveness from pellet formulations is also a lot 
enhanced with respect to the single-unit dosage forms. They 
are proper system for film coating concerning the low 
surface area-volume ratios. Also, confrontation to peripheral 
factors such as moisture, air and light are the most valuable 
properties of these dosage forms 1. Pellets have been exten-
sively explored to build up controlled and delayed release 
oral formulations that release the active constituents in the 
gastrointestinal tract at prearranged rates. They are 
extensively accepted due to their straight action to objective 
tissue so as to get the most out of the drug delivery at the 
preferred site of action within the definite time period in the 
gastrointestinal tract. Pellets are less vulnerable to dose 
clearance and customized release profiles (pulsed, sustained 
or delayed) can be achieved by careful selection of polymers 
and method of preparation. Different chemically attuned as 
well as contrary pellets can be united collectively and 
conveyed in the gastrointestinal tract either at the similar 
sites or dissimilar sites. Scientifically, pellets are significantly 
spherical instinctively strong agglomerates of powder 
particles, organized by a specialized granulation process, 
known as pelletization, which was fashioned by the 
agglomeration of fine powdered adjuvants and drugs 
collectively that directs to the creation of small free flowing 
powders of spherical or semi spherical sizes2. 
MATERIALS AND METHODS 
Materials 
Materials and Methods: Glipizide was a gift sample from 
Sidmak Laboratories, Gujarat and all other 
chemicals/reagents used were of analytical grade and 
standard.  
Methods: 
Preparation of drug solution layer:-  
Pan coating method was employed in order to set up 
spherical pellets. Glipizide 0.5 gm was integrated into non-
pareils seeds by spurting glipizide in a solution in methylene 
chloride containing polyvinyl pyrolidone (PVP 30K) as a 
binder 10 gm and talc 20 gm as antiadherants. The declared 
amounts of glipizide and PVP K 30 were suspended in 
methylene chloride solution separately. After mixing each 
solution for a certain period of time, these two solutions 
were mixed together and necessary amount of methylene 
chloride is added up to the desired volume was made. The 
coating solution was sprayed over the non-pareils seed by 
using Laboratory size coating  machine with the speed of 
20rpm.The pressure of the spray gun was set at 4 atm and 
1200 ml coating solution was misted over 70gm of non 
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pareil seeds . No heating was applied during the preparation 
for drying the pellets.The pellets were dehydrated at room 
temperature up to an invariable weight3.  
Table 1: Composition of core pellets 
Ingredients Quantity in gm 
Glipizide 0.5 
Polyvinylpyrollidone (PVP  K 30 ) 10.0 
Talc Q.S. 20.0 
Methylene Chloride Q.S. 300ml 
 
Preparation of drug loaded pellet: (without 
Glutareldehyde) 
The chitosan Solution was prepared by dissolving the stated 
amount of chitosan, i.e.1 gm (F1) and 1.25gm (F2) in 1% 
acetic acid solution make volume upto 100ml. Stirred for 30 
mins by using stirrer. 100 gm of drug loaded pellets were 
used for coating. The  chitosan solution was sprayed radially 
using spray gun onto the rotating glipizide loaded pellets 
and very small amount of talc powder was sprayed onto the 
pellets intermittently to avoid the agglomeration of the 
pellets. The pellets were dried at 60° c temperature in 
vacuum oven up to 24 h. Weight gain achieved was 10% 
w/w and 20% w/w respectively4. 
preparation of drug loaded pellet: (with Gluteraldehyde) 
The chitosan Solution was prepared by dissolving the stated 
amount of chitosan, i.e.1 gm in 1% acetic acid solution make 
volume upto 100ml. Stirred for 30 mins by using a magnetic 
stirrer. 5 ml of Gluteraldehyde (0.5 to 5 %) is added to the 
chitosan solution, and then this solution stirred for another 
1 hr at a magnetic stirrer then volume was made upto the 
mark and these solutions  were kept for about 30 
minutes.100 gm of drug loaded pellets were used for 
coating. The crosslinked chitosan solution of different % of 
gluteraldehyde was sprayed radially using spray gun onto 
the rotating glipizide loaded pellets and very small amount 
of talc powder was sprayed onto the pellets intermittently to 
avoid the agglomeration of the pellets. The pellets were 
dried at 60° c temperature in vacuum oven up to 24 h 4. The 
pellets obtained are  named  as F3(0.5%),F4(1.0%), 
F5(2.0%), F6(3.0%),F7(4.0%) and F8(5.0%) according to 
the concn of Gluteraldehyde taken. 
 
Table 2: Composition of coating solution for core pellets 
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 
Glipizide 
(pellets) 
100gm 100gm 100gm 100gm 100gm 100gm 100gm 100gm 
Chitosan 1.0mg 1.25gm 1.0gm 1.0gm 1.0gm 1.0gm 1.0gm 1.0gm 
Acetic Acid 
Solution(%v/v) 
1.0 1.0 1.0 1.0 1.0 1.0 1.0 1.0 
Gluteraldehyde(%) ----- ------- 0.5 1.0 2.0 3.0 4.0 5.0 
Talc q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. 
Water q.s. q.s. q.s. q.s. q.s. q.s. q.s. q.s. 
 
Evaluation of pellets5: The pellets were portrayed by their 
micromeritic possessions, such as, flow properties, bulk 
density, tapped density, and Hauser ratio.  
Angle of repose:- 
Angle of repose q of the pellets, which measures the 
resistance to particle flow, was determined by a fixed funnel 
method  and calculated as Tan q = 2H / D, Where H is the 
height of the pellets heap and D is diameter of the spherical 
surface of the pellets heap that is formed on a graph paper 
after making the pellets flow from the glass funnel. 
 Bulk Density:-Apparent bulk density was found out by 
introducing some fixed weight of pellets into graduated 
cylinder and calculating the volume. Bulk Volume will be 
estimated by tapping the graduated cylinder in bulk density 
apparatus up to a fixed volume obtained. The final volume is 
known as bulk volume. Bulk density was calculated by the 
formula, 
Bulk density (g/ml) = Weight of sample in grams / Bulk 
volume.  
Tapped Density-The tapping method was applied to find 
out the tapped density as follows, Tapped density = Weight 
of sample / Volume of pellets after tapping 50 times 
Hauser ratio- It gives a suggestion of the degree of 
densification which could effect from vibration of the feed 
hopper. 
 Hauser ratio= Tapped density/ Fluff density. 
 Lower Hausner’s ratio = Better flowability, Higher 
Hausner’s ratio = poor flowability 
 Friability  - The test of Friability was carried out by using 
20 pellets (Roche friabilator). Friability of the crosslinked 
chitosan coated pellets as characterization parameters were 
evaluated.  
Drug content  100 mg of glipizide loaded pellets were 
triturated to get fine powder, and then it was transferred 
into 100 ml volumetric flask and dissolved in 100 ml 
phosphate buffer at pH 7.4. The resulting mixture was 
stirred up on an orbital shaker for 24 h. Quantity of samples 
equivalent to 10mg of glipizide were taken, filtered through 
0.45 μm whatman filter paper, diluted suitably and analysed 
at 276 nm using spectrophotometer. The assay was 
performed  and mean values were taken. 
Scanning electron microscopy (SEM) 
The morphology of pellets were studied by scanning 
electron microscopy (SEM), which was performed to 
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characterize the surface of formed pellets. SEM photographs 
of the chitosan coated nonpareil pellets of glipizide were 
taken before and after coating. The coated pellets were 
scanned and the micrographs were examined. 
In vitro Drug release studies 
A USP basket apparatus has been used to study in-vitro drug 
release from pellets. 
The dissolution test for coated pellets equivalent to 10mg 
was performed in using dissolution test apparatus. The 
dissolution test was performed using 900 ml pH 7.4 buffer, 
at 37 ± 0.5°C and 100 rpm. The volume was replenished with 
the same amount of fresh dissolution fluid each time to 
maintain the sink condition. Withdrawn samples (10 mL) 
were analyzed spectrophotometrically at 276 nm . Then the 
cumulative percentage drug release was calculated. 
Stability studies of the optimized formulation  
The stability studies were carried out according to ICH and 
WHO guidelines to assess the drug and formulation stability. 
Best found formulation that is F8 was sealed in aluminum 
packaging having a polyethylene coating on the inside. 
Samples were kept in a humidity chamber maintained at 
40°C and 75% RH for 3 months .At the end of studies, 
samples were analyzed for the drug content, in vitro release 
profile and other physicochemical parameters. 
RESULT AND DISCUSSION 
Characterization of Glipizide: 
Melting point determination: The melting point of 
Glipizide was determined by Melting point apparatus    using 
capillary method. It was found to be 208°C which complies 
with reported value6. 
Evaluation of Chitosan Coated Pellet (Non Cross Linked 
with Gluteraldehyde) 
Micromeritic properties:  
The effect of polymer concentration on the micromeritic 
properties of pellets was studied. The mean particle size of 
pellets increased with an increasing polymer concentration. 
This  may  be  due  to increased total  solids onto the  pellets , 
which  resulted  in uniform  coating may lead to uniform 
particle  size distribution. Coating  of  the  non  pareils  did 
not  have significant  effect  on flow  properties  of  the  
pellets  as  shown in Table -1 because  non pareils possess 
definite structure and mechanical strength7. 
 
Table 3: Micromeritic properties of chitosan coated glipizide loaded pellets 
Formulation Bulk densitya 
(gm/ml) 
Tapped densitya 
(gm/ml)) 
Angle of 
reposea 
Hausner 
ratioa 
Loss on 
dryinga (%)  
F1 0.714 ±0.11 0.725 ±0.03 15.01±0.02 1.013±0.23 3.08 ± 0.27 
F2 0.723±0.02 0.735±0.01 16.61±0.30 1.014±0.30 3.51±0.35 
   a Mean ± SD; n = 3. 
 
Angle of repose of pellet formulation was found to be 15.01 
and 16.61 for F1 and F2 respectively which shows that 
pellets exhibit excellent flow properties. Hausner ratio 
closer to 1 indicates good flow property and packing ability.   
Friability Test of the formulations: 
Results of friability test for chitosan coated pellets were 
found out be 0.03% for F1 and 0.04% for F2. Pellet 
formulations F1 and F2 achieved friability values less than 
1% as per USP limit for tablets. Thus all pellets passed the 
USP friability test.   
 Drug Content: 
Drug content of chitosan coated non pareils was found out to 
be 98.00% for F1 and 97.25% for F2. So the drug content 
was found out be within the limit. 
 In vitro Drug release studies:  
Spectrophotometer Method Development for Estimation 
of Glipizide in Bulk: 
Selection of wavelength for analysis and preparation of 
standard calibration curve in Phosphate buffer pH (7.4) 
 Selection of Analytical wavelength: 
UV- spectrum: 
The spectrum of glipizide showed considerable linearity at 
wavelength 276 nm in phosphate buffer (pH 7.4). This 
wavelength was used for determination of drug content of 
formulation, in vitro drug dissolution studies. 
 
Figure 1: UV spectrum of Glipizide. 
Standard Curve8: 
Calibration curve was prepared by taking absorption of 
diluted stock solutions at wavelength 276 nm. Beer’s law 
was obeyed in the concentration range 5-50 µg/ml. 
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Table 4: Standard curve of Glipizide in phosphate buffer 
(pH 7.4) 
Sr.No. Concentration 
(µg/ml) 
Absorbance 
1 5 0.1449 
2 10 0.2548 
3 15 0.3995 
4 20 0.5441 
5 25 0.6487 
6 30 0.7761 
7 35 0.9082 
8 40 1.0225 
9 45 1.1574 
10 50 1.2756 
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Figure 2: Calibration Curve of Glipizide in 
phosphate buffer pH 7.4 
The standard curves with equations for regression line and 
R2 values are given below. Standard curve with phosphate 
buffer (pH 7.4) was used for drug content evaluation and for 
dissolution studies. 
Y= 0.0252x+0.0189 (R2 = 0.9994) 
In vitro dissolution studies of glipizide from different pellets 
were performed in phosphate buffer (pH 7.4) using USP 
Type I dissolution test apparatus. In vitro release 
experiments were evaluated in order to investigate the effect 
of chitosan polymer and the amount of the polymer content 
on the release pattern of pellets loaded with 
glipizide.Chitosan has high water-solubility and swelling 
properties in aqueous media. Percentage release of chitosan 
coated formulations (F1 and F2) was shown in Table 3. 
Table 5: Dissolution study of chitosan coated 
glipizide loaded pellets 
Time (Hrs) Cumulative % Drug Release 
F1 F2 
1 48.98 40.36 
2 52.28 46.21 
3 60.23 55.25 
4 68.45 63.06 
5 79.12 70.28 
6 84.23 77.87 
7 89.86 82.41 
8 96.25 93.87 
a Mean ± SD; n = 3. 
Dissolution profile of chitosan coated pellets showed that 
the burst release of drug from the pellets it might due to the 
high aqueous solubility of chitosan. The basic molecular 
parameters of chitosan, like molecular weight and degree of 
deacetylation, influence the drug release. Chitosan is 
hydrophilic, retains water in its structure and forming gels 
spontaneously6. In the present study chitosan used was of 
86% deacylated. The chitosan with high degree of 
deacylation showed a low degree of swelling7, hence 
formulation showed the burst release, and also the poor gel 
formation of chitosan in phosphate buffer pH 7.4 also 
contributed the fact8. As the coating thickness increased 
onto the glipizide pellets the release was slightly decreased. 
Formulation F1 and F2 showed the 96.25% and 
93.87%release in 8 h which is shown in Fig.03. 
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Figure 3: Dissolution profile of chitosan coated glipizide loaded pellets 
 Drug release models9: 
It was found that Formulations F1 and F2 showed 96.25% and 93.87 % in 8 hours. The value of n was found to 0.34 and 0.403 
for F1 and F2 respectively, which indicate that formulations followed Korsemeyer-Peppas model for drug release. 
 
Kar et al                                                                                                                 Journal of Drug Delivery & Therapeutics. 2019; 9(4-A):237-245  
ISSN: 2250-1177                                                                                  [241]                                                                                 CODEN (USA): JDDTAO 
6.6.1.1.6. Morphology of coated non pareils (SEM):  
          
[A]                                                                          [B] 
Figure 4: SEM Photograph of Chitosan coated pellets 
A – Non pareils.  B – Chitosan coated pellets. 
 
The view of the non pareils showed a smooth surface 
whereas coated pellets showed the rough /porous surface 
structure is caused due to rapid loss of moisture from the 
wet mass with a high liquid content. From the SEM data it 
was clear that chitosan pellets showed the burst release, 
because of the pellet get eroded. 
Evaluation of Cross linked Chitosan Pellets (with 
Gluteraldehyde) 
 Micromeritic properties:10 
Coating  of  the  non  pareils  did not  have significant  effect  
on flow  properties  of  the  pellets  as  shown in Table 24 
because non pareils possess defined structure and 
mechanical strength. The angle of repose of pellets ranged 
from 13.84 ±0.2to 17.12±0.1. The values of angle of repose 
and Hausner ratio indicate excellent flowing properties. 
Micromeritic properties are mentioned in Table 05. 
 
Table 6: Micromeritic properties of cross-linked chitosan coated glipizide loaded pellets 
Formulation Bulk densitya 
(gm/ml) 
Tapped densitya 
(gm/ml)) 
Angle of 
reposea 
Hausner 
ratioa 
Loss on 
dryinga (%) 
F3 0.8523±0.03 0.923±0.02 14.31±0.02 1.083±0.01 3.08 ±0.3 
F4 0.8142±0.04 0.825±0.28 15.12 ±0.1 1.014±0.02 2.98 ±0.18 
F5 0.8232 ±0.1 0.835 ±0.4 13.84 ±0.2 1.014 ±0.1 3.24 ±0.2 
F6 0.8146±0.02 0.822±0.04 16.52±0.01 1.0095±0.3 3.10 ±0.32 
F7 0.8525±0.04 0.893±0.01 17.12±0.1 1.047±0.04 3.45 ±0.2 
F8 0.8120±0.11 0.867±0.3 16.71±0.15 1.067±0.03 3.34 ±0.4 
           F: Formulations  a Mean ± SD; n = 3. 
Friability of the formulations11: 
Friability of the crosslinked chitosan coated pellets as 
characterization parameters were evaluated and the results 
in the range of 0.02 to 0.20 %. All pellet formulations 
achieved friability values less than 0.4%. Thus all pellets 
passed the USP friability test.  Values of friability test are 
mentioned in Table 06. 
Table 7: Friability of crosslinked chitosan coated 
glipizide loaded pellets 
Formulation Friabilitya(%) 
F3 0.20 
F4 0.05 
F5 0.10 
F6 0.04 
F7 0.02 
F8 0.03 
a Mean ± SD; n = 3. 
Drug Content:12 
Drug content of crosslinked chitosan coated non pareils was 
found out to be in the range of 94.63% to 98.60% for 
formulation F3 to F8.So the drug content was found out be 
within the limit which shown in Table 07. 
Table 8: Drug content of crosslinked chitosan coated 
glipizide loaded pellets 
Formulation Drug Contenta (%) 
F3        96.30 
F4 94.63 
F5 98.00 
F6 95.12 
F7 98.60 
F8 97.25 
a Mean ± SD; n = 3. 
In vitro Drug release studies:13  
In vitro dissolution studies of glipizide from different pellets 
were performed in phosphate buffer (pH 7.4) using USP 
Type I dissolution test apparatus. The in vitro release 
experiments were evaluated in order to investigate the effect 
of the crosslinker and the polymer on the drug release from 
the pellet formulations. Chitosan exhibits pH-dependant 
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swelling and controlled drug release properties. The 
chitosan is hydrophilic in nature in acidic media due to the 
presence of the amino group, but hydrophilicity and 
solubility of chitosan is changed on covalent crosslinking 
with aldehydes. However, the variations in hydrophilicity 
depend on the type of crosslinker and chitosan used for 
crosslinking. The cross-linking density has a remarkable 
effect on the release of drugs from the chitosan matrix 
systems. Higher densities tend to slow drug release more 
than lower densities. Crosslinking with gluteraldehyde 
increase the hydrophobic character in chitosan. It was 
observed that increase in concentration of gluteraldehyde, 
the release of the glipizide from the pellets is retarded and 
vieversa9. Formulation F3, F4, F5 and F6 showed the 
glipizide release 95.02%, 95.93%, 92.93% and 92.20% in 9, 
10 and 11 h. respectively which is shown in Table 27. From 
the dissolution profile it is understood that as the 
percentage of gluteraldehyde increases the drug release was 
retarded. Formulation F7 and f8 showed the drug release 
90.86% and 88.73% in 12 h., although the formulation F7 
and F8 showed drug release similar but the formulation F8 
showed the initial release less as compared to the 
formulation F7.  
Table 09: Dissolution study of cross linked 
chitosan coated glipizide loaded pellets 
Time 
(Hrs) 
Cumulative % drug release 
F3 F4 F5 F6 F7 F8 
1 39.28 32.63 28.33 22.75 18.04 12.22 
2 51.68 42.55 40.76 36.49 25.02 16.5 
3 58.63 51.68 49.43 44.49 30.70 21.98 
4 66.05 59.85 58.56 50.74 36.26 25.75 
5 72.88 67.60 62.36 58.43 41.68 38.33 
6 80.67 75.23 68.34 64.48 51.97 46.14 
7 85.02 85.64 73.06 69.33 61.31 55.17 
8 88.24 87.89 79.59 72.28 66.30 63.08 
9 95.02 93.29 84.34 80.79 75.54 69.33 
10 - 95.93 87.23 84.41 80.88 78.81 
11 - - 92.93 92.2 85.56 84.16 
12 - - - - 90.86 88.73 
a Mean ± SD; n = 3.
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Figure 04: Dissolution profile of crosslinked chitosan coated glipizide loaded pellets 
 
Drug release models:14 
In vitro dissolution studies of glipizide pellets coated with 
crosslinked chitosan were performed in phosphate buffer 
(pH 7.4) for 12 h using USP Type I dissolution test 
apparatus.  In case  of  controlled or  sustained release  
formulations, diffusion, swelling  and erosion are  the  three  
most important  rate  controlling  mechanisms. Formulations  
containing swelling polymers showed swelling as well as 
diffusion mechanism, because in addition to diffusion, 
processes  includes  relaxation of  polymer  chains, 
imbibitions  of  water causing polymer to swell and changing 
them from initial glassy to rubbery state. Peppas described 
the concept drug release mechanism, values of n i.e. release 
exponent for formulations are given in Table, value of n as 
0.5 indicates diffusion-controlled drug release and for the 
value 1.0 it indicates swelling-controlled drug release. Value 
of n between 0.5 and 1.0 can be regarded as an indicator for 
both the phenomenon (anomalous transport). the value of n 
from 1.0 to1.4 (i.e. more  than 1.0)  which indicates  the  
release  mechanism  following  anomalous  transport, Case II 
transport and  super case –II transport, respectively. 
Formulation F3 to F6 followed the peppas model and 
formulation F4 followed the matrix model, which describes 
the drug release as a diffusion process. Formulation F8 
followed the zero order kinetics which is shown Table 09. 
Table 10: Results of Kinetic treatment of Glipizide from 
pellet formulations (F3-F8) 
F Best Fit Model R n k 
F3 Peppas 0.9983 0.3995 38.7733 
F4 Matrix 0.9989 0.2960 30.6638 
F5 Peppas 0.9997 0.4880 28.6655 
F6 Peppas 0.9981 0.5585 23.6099 
F7 Peppas 0.9884 0.6903 15.6410 
F8 Zero 0.9967 1.010 9.6882 
R- Regression coefficient, n – Release exponent and k- 
Proportionality constant
. 
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 Morphology of coated non pareils (SEM): 15   
      
[C]                                                                     [D] 
Figure 5: SEM Photograph of crosslinked chitosan coated pellets 
C – Non Pareils.      D - Crosslinked chitosan coated. 
SEM of the crosslinked chitosan surface having the less cracks and surface of pellets more compact than the chitosan coated 
pellets, hence it can be correlated that dissolution profile of the chitosan and crosslinked coated pellets which is shown in Fig. 
05 
Drug-Excipient Compatibility-16 
IR Spectrum Interpretation:    The IR spectrum of Glipizide is shown in Fig.06 
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Figure-06 IR spectrum interpretation of Glipizide pure drug 
Table 11: IR spectrum interpretation of Glipizide pure drug 
Wave number(cm-1) Assignment 
3354 N-H stretching of NH2 
2943 C-H2 Aliphatic group 
1689 C = O stretching 
1651 C = N Aliphatic group 
1529 C – H stretching 
 
Interpretation of Covalent bonding in IR spectrum(cm-1) 
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Figure-07-IR Spectra of Glipizide-Chitosan (non cross linked) 
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Figure 08:  IR Spectra of Glipizide-chitosan cross linked with Gluteraldehyde 
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Figure-09-IR spectrum Analysis of PVP K 30 + Drug 
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Figure-10-IR spectrum Interpretation of Talc + Drug 
 
IR spectra of various glipizide-chitosan mixture(non 
crosslinked and cross linked) showed no interaction with 
the drug and prominent peaks of the drug were not affected.  
Thus, no interaction was observed between the drug and 
excipients. Hence drug excipients compatibility was 
established. There was neither shift and nor disappearance 
of characteristic peaks suggesting that there is no interaction 
between glipizide and other excipients or no degradation in 
drug molecule. 
Stability studies:17 
The stability studies were carried out on optimized 
formulation. The samples were stored at 400C ± 2ºC/75% ± 
5 % RH for three months to access their stability. The 
protocol of stability  studies  were  in compliance  with WHO  
guidelines  for  stability  testing  intended for the global 
market. After 30 days samples were withdrawn and retested 
for drug content and drug release studies. The best found 
formulations F8, F11 and F14 did not show any significant 
change in drug content when kept at different condition and 
periods. No significant difference in values of % drug release 
after 12 h observed during the stability studies. It indicates 
that irrespective of concentration of polymer, this 
formulation was able to retain its stability. 
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Table 12: Stability studies of selected formulations 
Time period 
Drug content (%) In vitro drug release after 12 hr (%) 
F2 F7 F8 F2 F7 F8 
Initial 97.25 98.60 97.25 93.87 90.86 88.73 
One month 
Ambient 96.35 96.53 96.86 93.67 90.34 88.51 
400c / 75%RH 96.01 95.48 96.39 93.23 90.13 88.12 
Two month 
Ambient 96.16 96.11 96.24 92.89 89.91 88.38 
400c / 75%RH 95.11 94.23 96.36 92.72 90.01 94.02 
Three month 
Ambient 95.89 96.01 96.16 84.01 88.23 93.51 
400c / 75%RH 93.76 93.65 95.10 82.78 86.89 92.78 
 
 
SUMMARY AND CONCLUSION 
Glipizide is an agent belonging to sulfonylurea group used 
for the treatment of non-insulin dependent diabetes mellitus 
(NIDDM).  Glipizide was administered once or twice in a day 
as tablet dosage form in dose regimen of 5 to 20 mg. The 
purpose of present work was to prepare sustained release 
pellets of glipizide in order to decrease the dosage regimen 
and to maintain the necessary blood concentration. Step by 
step studies were carried out to develop formulation of 
pellets using solution layering method. Non pareils (inert 
materials) were loaded with drug solution. To achieve 
sustained release of drug from the pellets, they were coated 
with polymer like chitosan and further cross linked with 
Gluteraldehyde. The differentnevaluation parameter was 
conducted among different formulations for knowing the 
effect of cross linking on the release study of glipizide. 
Pellets were evaluated for micromeritic properties as well as 
for in - vitro drug release in pH 7.4 phosphate buffer. The 
best found formulations were subjected to the stability 
studies. 
Following conclusions may be drawn from the study: 
 Amongst all formulation, pellets prepared by solution 
layering on non pareils and coated with  polymer 
showed that by varying the polymer concentration 
better sustained  release could be achieved in non 
cross linkers i,e  F2 have shown better drug release 
parameters than F1. 
 Pellets coated  by using crosslinking reaction shown 
better sustained  release than normal coating. 
 The increase in concentration of crosslinking agent 
shown more sustained release from the evaluation of 
finished formulations. 
 The best found formulation showed the in vitro drug 
release studies revealed that formulation-8(F8) shown 
better sustained  release for 12 h. 
 Best three formulation(F2,F7,F8) are subjected to 
accelerated stability studies shown no significant effect 
on the drug content and in vitro drug release from the 
formulation, hence it is quite stable at 40°C and 75% 
R.H. for three months. 
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